{"disease":{"id":"friedreich-s-ataxia","name":"Friedreich’s ataxia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"omaveloxolone","indication_name":"Friedreich’s ataxia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skyclarys","generic_name":"OMAVELOXOLONE","company_name":"Biogen Us","drug_phase":"marketed","molecular_target":"Nuclear factor erythroid 2-related factor 2","drug_class":"","quality_score":55,"revenue":"300","mechanism":"Skyclarys works by activating the Nrf2 pathway to increase the production of antioxidant proteins that protect cells from damage."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02593773","title":"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04102501","title":"A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Biojiva LLC","has_results":true},{"nct_id":"NCT01728064","title":"Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"PTC Therapeutics","has_results":false},{"nct_id":"NCT01898884","title":"Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02797080","title":"Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07095062","title":"Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome.","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"IRCCS Eugenio Medea","has_results":false},{"nct_id":"NCT07444333","title":"Cardiac Output and Fatigue in Friedreich's Ataxia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Scott Barbuto","has_results":false},{"nct_id":"NCT07123142","title":"FRIEDREICH ATAXIA- STEROIDOGENESIS","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Istanbul University","has_results":false},{"nct_id":"NCT07180355","title":"A Study of SGT-212 Gene Therapy in Friedreich's Ataxia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Solid Biosciences Inc.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}